SCHEMBL1707214

SCHEMBL1707214

C[N+]1(C)CCC(OC(=O)Cc2cccc(C3CCCC3)c2O)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 15/20 0.42
CHRM2 P08172 10/20 0.42
CHRM4 P08173 3/20 0.42
CHRM5 P08912 3/20 0.42
CHRM1 P11229 3/20 0.42
KCNH2 Q12809 2/20 0.42
HRH1 P35367 1/20 0.42
HTR2B P41595 1/20 0.42
LMNA P02545 3/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C19 P33261 1/20 0.37
SLC6A4 P31645 1/20 0.37
HSD17B10 Q99714 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
SLC22A1 O15245 1/20 0.37
THRB P10828 2/20 0.35
BLM P54132 2/20 0.35
PMP22 Q01453 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2340421 1.00 CHRM3 (0.42) CHRM3CHRM2CHRM4CHRM5CHRM1
SCHEMBL5473748 1.00 CHRM3 (0.42) CHRM3CHRM2CHRM4CHRM5CHRM1
Bromide SCHEMBL417945 0.99 CHRM3 (0.43) CHRM3CHRM2CHRM4CHRM5CHRM1
Iodide SCHEMBL5386794 0.99 CHRM3 (0.42) CHRM3CHRM2CHRM4CHRM5CHRM1
Hydrochloric Acid SCHEMBL1997630 0.99 CHRM3 (0.42) CHRM3CHRM2CHRM4CHRM5CHRM1
SCHEMBL8449813 0.99 CHRM3 (0.42) CHRM3CHRM2CHRM4CHRM5CHRM1
SCHEMBL7142072 0.99 CHRM3 (0.42) CHRM3CHRM2CHRM4CHRM5CHRM1
SCHEMBL7143841 0.99 CHRM3 (0.42) CHRM3CHRM2CHRM4CHRM5CHRM1
Bromide SCHEMBL1996228 0.99 CHRM3 (0.43) CHRM3CHRM2CHRM4CHRM5CHRM1
Bromide SCHEMBL2335688 0.99 CHRM3 (0.43) CHRM3CHRM2CHRM4CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210401740-A1 METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC COPD WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS SUNOVION RESPIRATORY DEVELOPMENT INC. (US) 2021-12-30 US disclosed
CN-113476429-A Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic agent 奇斯药制品公司 2021-10-08 CN disclosed
CN-113143894-A Stable pressurized aerosol solution compositions of glycopyrronium bromide and formoterol in combination 奇斯药制品公司 2021-07-23 CN disclosed
CN-105848641-B Stable pressurized aerosol solution compositions of glycopyrronium bromide and formoterol in combination 奇斯药制品公司 2021-07-09 CN disclosed
US-10940110-B2 Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations SUNOVION RESPIRATORY DEVELOPMENT INC. (US) 2021-03-09 US disclosed
CN-111150728-A Stable pressurized aerosol solution compositions of glycopyrronium bromide and formoterol in combination 奇斯药制品公司 2020-05-15 CN disclosed
EP-3151812-B1 INHALATION PARTICLES COMPRISING A COMBINATION OF AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC CHIESI FARM SPA (IT) 2020-04-22 EP disclosed
US-20190254967-A1 METHOD AND SYSTEM FOR THE TREATMENT OF CHROIC COPD WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS ELEVATION PHARMACEUTICALS, INC. 2019-08-22 US disclosed
EP-3311820-A1 METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS Sunovion Respiratory Development Inc. (US) 2018-04-25 EP disclosed
US-20170202787-A1 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED BETA 2-AGONIST OR COMBINED NEBULIZED BETA 2-AGONIST AND ANTICHOLINERGIC ADMINISTRATION ELEVATION PHARMACEUTICALS, INC. 2017-07-20 US disclosed
US-20140255491-A1 Method and System For the Treatment of Chronic Obstructive Pulmonary Disease With Nebulized Anticholinergic Administrations SUNOVION RESPIRATORY DEVELOPMENT INC. (US) 2014-09-11 US disclosed
US-20140018406-A1 Treatment of Chronic Obstructive Pulmonary Disease With Nebulized Beta 2-Agonist or Combined Nebulized Beta 2-Agonist and Anticholinergic Administration SUNOVION RESPIRATORY DEVELOPMENT, INC. (US) 2014-01-16 US disclosed
EP-2440196-A1 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED BETA 2-AGONIST OR COMBINED NEBULIZED BETA 2-AGONIST AND ANTICHOLINERGIC ADMINISTRATION Elevation Pharmaceuticals, Inc. (US) 2012-04-18 EP disclosed
US-20110132355-A1 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED BETA 2-AGONIST OR COMBINED NEBULIZED BETA 2-AGONIST AND ANTICHOLINERGIC ADMINISTRATION SUNOVION RESPIRATORY DEVELOPMENT INC. 2011-06-09 US disclosed
WO-2010144628-A2 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED BETA 2-AGONIST OR COMBINED NEBULIZED BETA 2-AGONIST AND ANTICHOLINERGIC ADMINISTRATION ELEVATION PHARMACEUTICALS, INC. (US) 2010-12-16 WO disclosed
EP-2257172-A2 METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS Elevation Pharmaceuticals, Inc. (US) 2010-12-08 EP disclosed
US-20100055045-A1 METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS SUNOVION RESPIRATORY DEVELOPMENT INC. 2010-03-04 US disclosed
WO-2009134524-A2 METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS ELEVATION PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed
US-20090215734-A1 METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS ELEVATION PHARMACEUTICALS, INC. (US) 2009-08-27 US disclosed
EP-1371645-A1 Process for the preparation of the 2'-(R)-Glycopyrronium Enantiomers and their use in medicaments Noe, Christian R. (AT) 2003-12-17 EP disclosed